11:37 AM EDT, 03/17/2025 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Monday that preliminary open-label safety data from its phase 3 clinical trial for GLSI-100, an immunotherapy to prevent breast cancer recurrences, appears consistent with prior trials, which showed a well-tolerated safety profile.

The Data Safety Monitoring Board for the trial met twice in 2024, most recently in December, and recommended continuing the study without modification, the company said.

In the phase 2b trial, GLSI-100 was associated with an 80% or greater reduction in metastatic breast cancer recurrence over five years of follow-up, compared to a 20% to 50% reduction by other approved products. Patients treated with GLSI-100 also remained disease-free over the first six months, the company added.

The treatment was well tolerated, with no serious adverse events reported, according to the company.

Shares of Greenwich LifeSciences ( GLSI ) were up nearly 7% in recent trading.

Price: 12.83, Change: +0.83, Percent Change: +6.92